TY - JOUR
T1 - Complement regulators in human disease
T2 - Lessons from modern genetics
AU - K.Liszewski, M.
AU - Atkinson, J. P.
N1 - Publisher Copyright:
© 2014 The Association for the Publication of the Journal of Internal Medicine.
PY - 2015/3/1
Y1 - 2015/3/1
N2 - First identified in human serum in the late 19th century as a 'complement' to antibodies in mediating bacterial lysis, the complement system emerged more than a billion years ago probably as the first humoral immune system. The contemporary complement system consists of nearly 60 proteins in three activation pathways (classical, alternative and lectin) and a terminal cytolytic pathway common to all. Modern molecular biology and genetics have not only led to further elucidation of the structure of complement system components, but have also revealed function-altering rare variants and common polymorphisms, particularly in regulators of the alternative pathway, that predispose to human disease by creating 'hyperinflammatory complement phenotypes'. To treat these 'complementopathies', a monoclonal antibody against the initiator of the membrane attack complex, C5, has received approval for use. Additional therapeutic reagents are on the horizon.
AB - First identified in human serum in the late 19th century as a 'complement' to antibodies in mediating bacterial lysis, the complement system emerged more than a billion years ago probably as the first humoral immune system. The contemporary complement system consists of nearly 60 proteins in three activation pathways (classical, alternative and lectin) and a terminal cytolytic pathway common to all. Modern molecular biology and genetics have not only led to further elucidation of the structure of complement system components, but have also revealed function-altering rare variants and common polymorphisms, particularly in regulators of the alternative pathway, that predispose to human disease by creating 'hyperinflammatory complement phenotypes'. To treat these 'complementopathies', a monoclonal antibody against the initiator of the membrane attack complex, C5, has received approval for use. Additional therapeutic reagents are on the horizon.
KW - Age-related macular degeneration
KW - Atypical haemolytic uraemic syndrome
KW - Complement regulation
KW - Eculizumab
KW - Genetics
KW - Therapeutics
UR - http://www.scopus.com/inward/record.url?scp=84923080145&partnerID=8YFLogxK
U2 - 10.1111/joim.12338
DO - 10.1111/joim.12338
M3 - Review article
C2 - 25495259
AN - SCOPUS:84923080145
SN - 0954-6820
VL - 277
SP - 294
EP - 305
JO - Journal of Internal Medicine
JF - Journal of Internal Medicine
IS - 3
ER -